Fever and Hyponatremia Unmasking Brugada Pattern Electrocardiogram in a Patient With SARS-CoV-2 Infection

Sarah Ayad 1, Ramez Alyacoub 1, Kirolos Gergis 2, Muhammad Atif Masood Noori 3,4, Sherif Elkattawy 4, Basel Abdelazeem 5, Raja Pullatt 6

Abstract

Brugada syndrome is an autosomal dominant genetic disorder that primarily affects myocardial sodium channels and has been associated with an increased risk of ventricular tachyarrhythmias and sudden cardiac death. Here, we report a case of a 58-year-old Hispanic male with a history significant for prior pulmonary tuberculosis infection who presented with pleuritic left-sided chest pain associated with body aches, productive cough, fevers, and chills and was found to be positive for SARS-CoV-2 by real-time reverse-transcription-polymerase chain reaction (rRT-PCR). Electrocardiogram (ECG, EKG) on presentation demonstrated a coved ST-segment elevation in V1-V2, suggesting Brugada pattern type 1 without evidence of ischemic changes. EKG changes normalized once fever and hyponatremia improved.

Introduction

Brugada syndrome is an autosomal dominant genetic disorder that affects the myocardial sodium channel triggering abnormal electrical activity in the heart [1,2]. Patients having typical EKG patterns who have experienced sudden cardiac death, or sustained ventricular arrhythmia is said to have Brugada syndrome. Brugada ECG pattern is characterized by pseudo right bundle branch block and persistent ST-segment elevation in leads V1-V3. Two distinct patterns of ST-elevation have been found; in type 1, the elevated ST-segment (>2 mm) descends with an upward convexity to an inverted T-wave, referred to as the “coved type” Brugada pattern. Type 2 (Saddleback type) the elevated ST segment descends toward the baseline, then rises again to an upright or biphasic T-wave [1,2]. Fever and electrolyte abnormalities are the most important triggers that contribute to EKG and clinical manifestations of Brugada syndrome. Management includes lifestyle modifications to avoid triggers, medications, and prevention of sudden cardiac death by implantable cardioverter-defibrillator [1,2]. We report a case of Brugada pattern induced by hyponatremia and fever associated with COVID-19.

Case Presentation

A 58-year-old Hispanic male with a history significant only for pulmonary tuberculosis diagnosed over a decade ago, who presented to the emergency department (ED) complaining of left-sided pleuritic chest pain that was localized, and sharp. This was associated with body aches, productive cough, fevers, and chills. He reported exposure to COVID-19. Additionally, the patient reported increased thirst and increased urination a few days prior to presentation. He denied any abdominal pain, nausea, vomiting, dizziness, lightheadedness, syncopal episodes, palpitations, or any other symptoms. He also denied any family history of sudden cardiac death. Vital signs on presentation were significant for a temperature of 99.9 degrees Fahrenheit, blood pressure of 120/70 mmHg, heart rate of 106 beats per minute (bpm), respiratory rate of 18 breaths per minute, and oxygen saturation of 95% on room air.

Complete laboratory values on presentation are listed in Table 1. Influenza A and B PCR were negative. The patient tested positive for SARS-CoV-2 by real-time reverse-transcription polymerase chain reaction (rRT-PCR). Chest x-ray (CXR) showed: large airspace consolidation in the left midlung which has a cavitary appearance and apiapical reticular opacities left more than the right as seen in Figure 1. Computed tomography (CT) of the chest showed multiple ground glass airspace opacities bilaterally in combination with dense areas of pulmonary consolidation particularly involving the left upper lobe with the consolidation of at least half of the left upper lobe as seen in Figure 2.
| Parameter                        | Reference Range   | Value | 
|---------------------------------|-------------------|-------|
| White Blood Count (WBC)         | 4.8-10.8 K/UL     | 10.3  |
| Hemoglobin                      | 14-18 gm/dL       | 12.9  |
| Platelet                        | 130 K-400 K       | 140   |
| Polysa                          | 42%-75%           | 93.2  |
| Absolute neutrophil count- Polys ABSA | 1.4-6.5 K/UL | 9.6   |
| Lymphs                          | 20.5-51.1         | 4.9   |
| Lymphs ABSA                     | 1.2-3.4 K/UL      | 0.5   |
| Lactic acid                     | 0.5-2.2 mmol/L    | 1.4   |
| Sodium                          | 136-144 mmol/L    | 116   |
| Potassium                       | 3.6-5.1 mmol/L    | 3.8   |
| Creatinine                      | 0.7-1.2 mg/dL     | 0.81  |
| Osmolality                      | 280-295 mosm/kG   | 242   |
| Brain Natriuretic Peptide (BNP) | <100 pg/mL        | 117   |
| Troponin                        | 0.00-0.08         | 0.03  |

**TABLE 1: Significant laboratory values upon presentation to the ED**

**FIGURE 1:** Initial chest x-ray showing large airspace consolidation in the left midlung which has a cavitary appearance. Biapical reticular opacities, left more than right.
An electrocardiogram on presentation demonstrated a coved ST-segment elevation in V1-V2 followed by a negative T-wave, suggesting Brugada pattern type 1 without evidence of ischemic changes (Figure 3). He was initially started on supplemental oxygen via nasal cannula, Tylenol, hydroxychloroquine, azithromycin, ceftriaxone, a regimen that was thought to be advantageous at that time. ECG changes were corrected with the resolution of fever and correction of electrolytes (Figure 3). Throughout the hospital stay, the patient’s oxygenation continued to worsen requiring non-invasive ventilation in the form of bilevel positive airway pressure (BiPAP) and eventually mechanical intubation due to progressively worsening hypoxemic respiratory failure. The hospital course was complicated by severe barotrauma, pneumothorax, hypotension requiring pressor support, atrial flutter, and several complicating bacterial respiratory tract infections. On day 54 of hospitalization, the patient went into a systolic cardiac arrest and despite maximum efforts and initiation of full ACLS protocol, the patient unfortunately died.
Discussion

Brugada syndrome is an autosomal dominant genetic disorder characterized by a pseudo-right bundle branch block and persistent ST-segment elevation on right-sided pericardial leads on the ECG in conjunction with an increased risk of ventricular tachyarrhythmias and sudden cardiac death. Mutation in the SCN5A gene, which encodes for the alpha subunit of voltage-gated sodium channels is responsible for 30% of all genetically identified Brugada syndrome. In the type 1 Brugada ECG pattern, the elevated ST segment (≥2 mm) descends with an upward convexity to an inverted T-wave, referred to as the "coved type" Brugada pattern. Whereas type 2 Brugada ECG pattern, the ST segment has a "saddleback" ST-T-wave configuration. The elevated ST segment descends toward the baseline, then rises again to an upright or biphasic T-wave [2]. Patients with typical ECG features who are asymptomatic and have no other clinical criteria are said to have the Brugada pattern. The diagnosis of Brugada syndrome is based on clinical criteria and ECG manifestations. Evidence of typical ECG manifestations and the presence of at least one of the following criteria are needed for the diagnosis of Brugada syndrome. These clinical criteria include a family history of sudden cardiac death in a relative younger than 45 years of age or the presence of ECG type 1 in a family member, ventricular tachyarrhythmia, or symptoms associated with arrhythmias such as seizures, nocturnal agonal respiration, or syncope [2].

Multiple factors have been found to trigger or unmask the Brugada pattern. The primary mechanism is the disruption of ionic gradients across myocyte membrane and the dysfunction of the sodium channels. Medications, including antiarrhythmics acting as sodium channel blockers, such as flecainide and propafenone, psychotropic medications, anesthetics such as propofol, and toxins such as cocaine [3]. Fever can also be a trigger for both inductions of Brugada pattern ECG abnormalities and cardiac arrest among persons known to have Brugada pattern ECG or Brugada syndrome. The mechanism is likely due to temperature-induced changes in the action potential and sodium channels [4]. Type 1 Brugada pattern was found to occur 20 times more in febrile patients than patients who are afebrile [5]. Fever was found to be the precipitating factor of cardiac arrest in 18% of Brugada syndrome arrests [6]. Another potential trigger is electrolyte disturbances such as hyperkalemia and hyponatremia [7]; hyponatremia has been reported in the literature as a rare trigger for the Brugada pattern [8]. It is suspected that severe hyponatremia diminishes the electrochemical ionic gradient by decreasing the inward sodium current and leaving the transient outward current unopposed [9]. When dealing with a mechanically ventilated patient who develops a Brugada pattern, an essential point to be aware of is to avoid certain anesthetics such as propofol, which is also known to trigger the Brugada pattern [10].

Brugada pattern has been noted to occur in systemic infections [11], including viral infections such as influenza [12], likely as a result of fever. COVID-19 is a newly recognized infectious disease that has caused a worldwide pandemic, presenting mainly with fever, pneumonia, and hypoxic respiratory failure. Upon performing a literature review in PubMed, we have found similar cases of COVID-19 and Brugada pattern with the resolution of the pattern following defervescence [13,14]. However, one case was reported by Lugtenbierl for a COVID-19 patient with a Brugada pattern that persisted despite the resolution of fever [15]. It is now well known that the COVID-19 causes extrapulmonary effects likely secondary to cytokine storm,
causing multisystem inflammation, and organ failure. Patients with COVID-19 are at risk of cardiovascular complications, including arrhythmias; [16] whether it is the inflammatory effects on the heart or direct myocardial injury that can unmask Brugada syndrome is yet to be investigated more. Our case report is unique in that this is the first case report to our knowledge where the presence of both fever and hyponatremia in a patient with COVID-19 has triggered Brugada ECG pattern.

Patients with Brugada pattern who are asymptomatic with no history of ventricular tachyarrhythmias or family history of sudden cardiac death have a low risk of arrhythmia or cardiac arrest; therefore, require no treatment apart from the control of provoking factors and monitoring [17]. On the other hand, for patients with Brugada syndrome, those who have survived sudden cardiac arrest, or those with a history of syncope due to ventricular tachyarrhythmias, implantable cardiac defibrillator device placement is the treatment of choice. In patients who refuse ICD or have a contraindication to ICD such as reduced life expectancy, drug therapy with quinidine or amiodarone is indicated [1,2,17]. Our patient had a Brugada pattern likely multifactorial due to fever and hyponatremia in the setting of COVID-19 infection. His EKG normalized after his fever resolved and hyponatremia improved. Unfortunately, he was intubated on mechanical ventilation and developed complications related to COVID-19 infection, and died later on.

Conclusions
In conclusion, we report a case of a 58-year-old man who presented to the emergency department with complaints of pleuritic chest pain associated with fever and generalized body ache, was positive for COVID-19, labs were significant for hyponatremia and on EKG found to have type 1 (coved) Brugada EKG pattern. Our patient’s EKG normalized once fever and hyponatremia improved. These patients should have serial EKG monitoring and aggressive antipyretic therapy to prevent life-threatening arrhythmia. Our case is unique and adds to the limited number of cases showing association of Brugada pattern EKG with fever and hyponatremia-induced by COVID-19.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Brugada J, Campuzano O, Arbello E, Sarquella-Brugada G, Brugada R: Present status of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2018, 72:1046-59. 10.1016/j.jacc.2018.06.037
2. Brugada R, Campuzano O, Sarquella-Brugada G, Brugada J, Brugada P: Brugada syndrome. Methodist Debakey Cardiovasc J. 2014, 10:25-8. 10.14797/mdcj-10-1-25
3. Tommy G, Freitas J: Induced Brugada syndrome: possible sources of arrhythmogenesis. Rev Port Cardiol. 2017, 36:945-56. 10.1016/j.rpc.2017.06.015
4. Manohar S, Dahal BR, Gitler B: Fever-induced Brugada syndrome. J Investig Med High Impact Case Rep. 2015, 3:2524709615577414. 10.1177/2324709615577414
5. Adler A, Topaz G, Heller K, et al.: Fever-induced Brugada pattern: how common is it and what does it mean?. Heart Rhythm. 2015, 10:1375-82. 10.1016/j.hrthm.2013.07.030
6. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL: Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med. 2008, 149:216-8. 10.7326/0003-4819-149-5-200808050-00020
7. Humak A, Humak B, Kuklen G, Onor OE: Brugada phenocopy induced by electrolyte disorder: a transient electrocardiographic sign. Ann Noninvasive Electrocardiol. 2016, 21:429-32. 10.1111/anec.12550
8. Ramsaroop K, Seecheran V, Persad S, Giddings S, Mohammad B, Seecheran NA: Suspected hyponatremia-induced Brugada phenocopy. Int Med Case Rep J. 2019, 12:61-5. 10.2147/IMCRJ.S200201
9. Agrawal Y, Aaggarwal S, Kalavakunta JK, Gupta V: All that looks like ‘Brugada’ is not ‘Brugada’: case series of Brugada phenocopy caused by hyponatremia. J Saudi Heart Assoc. 2016, 28:274-7. 10.1016/j.shja.2016.02.005
10. Weiner JB, Haddad EV, Raj SR: Recovery following propofol-associated brugada electrocardiogram. Pacing Clin Electrophysiol. 2010, 33:e39-42. 10.1111/j.1540-8199.2009.02589.x
11. Pflrman KS, White CA, Kelii A, Modl HC: Brugada syndrome manifesting only during fever in patient with septic shock secondary to post-obstructive pneumonia. Am J Case Rep. 2018, 19:1511-6. 10.12659/AJCR.911256
12. Baranchuk A, Simpson CS: Brugada syndrome coinciding with fever and pandemic (H1N1) influenza. CMAJ. 2011, 183:SRZ. 10.1503/cmaj.100016
13. Vidovich MI: Transient Brugada-like electrocardiographic pattern in a patient with COVID-19. JACC Case Reports. 2020, 2:1245-9.
14. van de Poll SWE, van der Werf C: Two patients with COVID-19 and a fever-induced Brugada-like electrocardiographic pattern. Netherlands Hear J. 2020, 28:7-8. 10.1016/j.nhj.2020.04.007
15. Lugenspiel P, Roth L, Seiz M, Zeier M, Katus HA, Merle U, Schweizer PA: The arrhythmogenic face of COVID-
19. Brugada ECG pattern during acute infection. Eur Heart J Case Rep. 2020, 4:1-2. 10.1093/ehjcr/ytaa230

16. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C: Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020, 31:1003-8. 10.1111/jce.14479

17. Gourraud JB, Barc J, Thollet A, Le Marec H, Probst V: Brugada syndrome: diagnosis, risk stratification and management. Arch Cardiovasc Dis. 2017, 110:188-95. 10.1016/j.acvd.2016.09.009